{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:25:49Z","timestamp":1788989149867,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["GSB-S-15-001"],"award-info":[{"award-number":["GSB-S-15-001"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-14-00010"],"award-info":[{"award-number":["AID-OAA-A-14-00010"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10461-019-02576-8","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T12:02:57Z","timestamp":1561723377000},"page":"637-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms"],"prefix":"10.1007","volume":"24","author":[{"name":"on behalf of the Quatro Study Team","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-0996","authenticated-orcid":false,"given":"R.","family":"Weinrib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. N.","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Shapley-Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beksinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mgodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Musara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mphili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. T.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"2","key":"2576_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11904-015-0261-0","volume":"12","author":"A Harrison","year":"2015","unstructured":"Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M. Sustained high HIV incidence in young women in Southern Africa: social, behavioral, and structural factors and emerging intervention approaches. Curr HIV\/AIDS Rep. 2015;12(2):207\u201315.","journal-title":"Curr HIV\/AIDS Rep."},{"issue":"6","key":"2576_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"2576_CR3","doi-asserted-by":"publisher","first-page":"20642","DOI":"10.7448\/IAS.19.1.20642","volume":"19","author":"A van der Straten","year":"2016","unstructured":"van der Straten A, Brown ER, Marrazzo JM, et al. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc. 2016;19(1):20642.","journal-title":"J Int AIDS Soc."},{"issue":"22","key":"2576_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121\u201332.","journal-title":"N Engl J Med"},{"key":"2576_CR5","unstructured":"Rees H, Delany-Morelwe S, Lombard C, et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. In: Paper presented at: Conference on Retroviruses and Opportunistic Infections, Boston 2015."},{"issue":"9749","key":"2576_CR6","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(10)61086-0","volume":"376","author":"S McCormack","year":"2010","unstructured":"McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329\u201337.","journal-title":"Lancet"},{"issue":"7","key":"2576_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/QAD.0b013e32834541d9","volume":"25","author":"SSA Karim","year":"2011","unstructured":"Karim SSA, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (London, England). 2011;25(7):957.","journal-title":"AIDS (London, England)."},{"issue":"5996","key":"2576_CR8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science"},{"issue":"5","key":"2576_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000000897","volume":"71","author":"KE Bunge","year":"2016","unstructured":"Bunge KE, Dezzutti CS, Rohan LC, et al. A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film. J Acquir Immune Defic Syndr. 2016;71(5):498\u2013505.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2576_CR10","unstructured":"Littlefield S, Zhang W, Schwartz J, et al. Clinical performance, acceptability, and optimization of fast-dissolve vaginal inserts designed for HIV-prevention: results from two clinical studies. In: Conference on HIV Research for Prevention (HIV R4P). Chicago, IL; 2016."},{"issue":"1","key":"2576_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-009-9082-7","volume":"11","author":"LC Rohan","year":"2009","unstructured":"Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009;11(1):78\u201387.","journal-title":"AAPS J"},{"issue":"6","key":"2576_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/COH.0b013e3283590632","volume":"7","author":"B Mensch","year":"2012","unstructured":"Mensch B, van der Straten A, Katzen L. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012;7(6):534\u201341.","journal-title":"Curr Opin HIV AIDS."},{"issue":"6","key":"2576_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/COH.0b013e3283582d4a","volume":"7","author":"KR Amico","year":"2012","unstructured":"Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7(6):542\u20138.","journal-title":"Curr Opin HIV AIDS."},{"key":"2576_CR14","unstructured":"Stata Statistical Software: Release 15 [computer program]. Version 15. College Station, TX: StataCorp LLC; 2017."},{"issue":"8","key":"2576_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159\u201367.","journal-title":"AIDS."},{"key":"2576_CR16","unstructured":"Minnis A, Roberts S, Agot K, et al. End-user research on Multipurpose Prevention Technologies (MPT) for HIV and pregnancy prevention: young women\u2019s ratings of three delivery forms in a randomized, cross-over study in Kenya and South Africa Paper presented at: International AIDS Society, Paris; 2017."},{"key":"2576_CR17","unstructured":"Dedoose [computer program]. Version 7.0.23. Los Angeles, CA; 2016."},{"issue":"5","key":"2576_CR18","doi-asserted-by":"publisher","first-page":"e25283","DOI":"10.1002\/jia2.25283","volume":"22","author":"ET Montgomery","year":"2019","unstructured":"Montgomery ET, Beksinska M, Mgodi N, et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J Int AIDS Soc. 2019;22(5):e25283.","journal-title":"J Int AIDS Soc."},{"issue":"2","key":"2576_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10461-017-1811-9","volume":"22","author":"ET Montgomery","year":"2018","unstructured":"Montgomery ET, Noguchi LM, Dai JY, et al. Acceptability of and adherence to an antiretroviral-based vaginal microbicide among pregnant women in the United States. AIDS Behav. 2018;22(2):402\u201311.","journal-title":"AIDS Behav"},{"issue":"3","key":"2576_CR20","doi-asserted-by":"publisher","first-page":"e0147743","DOI":"10.1371\/journal.pone.0147743","volume":"11","author":"A Nel","year":"2016","unstructured":"Nel A, Bekker LG, Bukusi E, et al. Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-saharan Africa. PLoS ONE. 2016;11(3):e0147743.","journal-title":"PLoS ONE"},{"issue":"7","key":"2576_CR21","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s10461-012-0215-0","volume":"16","author":"A van der Straten","year":"2012","unstructured":"van der Straten A, Montgomery E, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16(7):1775\u201386.","journal-title":"AIDS Behav"},{"issue":"1","key":"2576_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1758-2652-13-30","volume":"13","author":"ET Montgomery","year":"2010","unstructured":"Montgomery ET, Woodsong C, Musara P, et al. An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc. 2010;13(1):30.","journal-title":"J Int AIDS Soc."},{"issue":"7","key":"2576_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/00007435-200307000-00005","volume":"30","author":"AM Minnis","year":"2003","unstructured":"Minnis AM, Shiboski SC, Padian NS. Barrier contraceptive method acceptability and choice are not reliable indicators of use. Sex Transm Dis. 2003;30(7):556\u201361.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"2576_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10461-009-9609-z","volume":"14","author":"ET Montgomery","year":"2010","unstructured":"Montgomery ET, Cheng H, van der Straten A, et al. Acceptability and use of the diaphragm and Replens\u00ae lubricant gel for HIV prevention in Southern Africa. AIDS Behav. 2010;14(3):629\u201338.","journal-title":"AIDS Behav"},{"issue":"1","key":"2576_CR25","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/s12889-017-4959-3","volume":"17","author":"R Eakle","year":"2017","unstructured":"Eakle R, Bourne A, Jarrett C, Stadler J, Larson H. Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography. BMC Public Health. 2017;17(1):968.","journal-title":"BMC Public Health."},{"issue":"7","key":"2576_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/apc.2017.0075","volume":"31","author":"A Van der Straten","year":"2017","unstructured":"Van der Straten A, Shapley-Quinn M, Reddy K, et al. Favoring \u201cPeace of Mind\u201d: a qualitative study of african women\u2019s HIV prevention product formulation preferences from the MTN-020\/ASPIRE Trial. AIDS Patient Care STDs. 2017;31(7):305\u201314.","journal-title":"AIDS Patient Care STDs."},{"issue":"9","key":"2576_CR27","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s10461-014-0804-1","volume":"18","author":"ST Roberts","year":"2014","unstructured":"Roberts ST, Heffron R, Ngure K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav. 2014;18(9):1701\u201311.","journal-title":"AIDS Behav"},{"issue":"1","key":"2576_CR28","doi-asserted-by":"publisher","first-page":"20875","DOI":"10.7448\/IAS.19.1.20875","volume":"19","author":"EH Luecke","year":"2016","unstructured":"Luecke EH, Cheng H, Woeber K, et al. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. J Int AIDS Soc. 2016;19(1):20875.","journal-title":"J Int AIDS Soc."},{"issue":"8","key":"2576_CR29","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1007\/s10461-018-2078-5","volume":"22","author":"AM Minnis","year":"2018","unstructured":"Minnis AM, Roberts ST, Agot K, et al. Young women\u2019s ratings of three placebo multipurpose prevention technologies for HIV and pregnancy prevention in a randomized, cross-over study in Kenya and South Africa. AIDS Behav. 2018;22(8):2662\u201373.","journal-title":"AIDS Behav"},{"issue":"1","key":"2576_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10461-017-1911-6","volume":"22","author":"R Weinrib","year":"2018","unstructured":"Weinrib R, Minnis A, Agot K, et al. End-users\u2019 product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018;22(1):133\u201345.","journal-title":"AIDS Behav"},{"issue":"3","key":"2576_CR31","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","volume":"21","author":"A van der Straten","year":"2018","unstructured":"van der Straten A, Agot K, Ahmed K, et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21(3):e25094.","journal-title":"J Int AIDS Soc."},{"key":"2576_CR32","volume-title":"The invisible product: preferences for long-acting injectable and implantable PrEP among South African youth","author":"E Montgomery","year":"2017","unstructured":"Montgomery E, Atujuna M, Ndwayana S, et al. The invisible product: preferences for long-acting injectable and implantable PrEP among South African youth. Paris: International AIDS Society; 2017."},{"key":"2576_CR33","unstructured":"Viguers S. 3-month vaginal ring for HIV prevention enters clinical trial: Healio Infectious Disease News; 2017."},{"issue":"2","key":"2576_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10461-016-1609-1","volume":"21","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, Mensch B, Musara P, et al. Misreporting of product adherence in the MTN-003\/VOICE Trial for HIV prevention in Africa: participants\u2019 explanations for dishonesty. AIDS Behav. 2017;21(2):481\u201391.","journal-title":"AIDS Behav"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-019-02576-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10461-019-02576-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-019-02576-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:45:11Z","timestamp":1593225911000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10461-019-02576-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2576"],"URL":"https:\/\/doi.org\/10.1007\/s10461-019-02576-8","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}